Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0)

Autor: Coombes, R. C., Badman, P. D., Lozano-Kuehne, J. P., Liu, X., Macpherson, I. R., Zubairi, I., Baird, R. D., Rosenfeld, N., Garcia-Corbacho, J., Cresti, N., Plummer, R., Armstrong, A., Allerton, R., Landers, D., Nicholas, H., McLellan, L., Lim, A., Mouliere, F., Pardo, O. E., Ferguson, V., Seckl, M. J.

Publikováno v: Nature Communications, 14(1):260. Nature Publishing Group UK
Coombes, R C, Badman, P D, Lozano-Kuehne, J P, Liu, X, Macpherson, I R, Zubairi, I, Baird, R D, Rosenfeld, N, Garcia-Corbacho, J, Cresti, N, Plummer, R, Armstrong, A, Allerton, R, Landers, D, Nicholas, H, McLellan, L, Lim, A, Mouliere, F, Pardo, O E, Ferguson, V & Seckl, M J 2023, ' Author Correction : Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0) ', Nature Communications, vol. 14, no. 1, 260 . https://doi.org/10.1038/s41467-023-35969-4

In the original version of this article, the following author (Veronica Ferguson) was omitted from the author list. Author list, Author contributions and competing interests statements have now been updated in both the PDF and HTML versions of the ar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::7e2e046860bc756a455c52bf62b45aab
https://research.vumc.nl/en/publications/b3ee0e28-5d1b-4b34-b1e8-b9b33e588db9

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Autor: de Boer S. M., Powell M. E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P. B., Ledermann J. A., Khaw P., Colombo A., Fyles A., Baron M. -H., Jurgenliemk-Schulz I. M., Kitchener H. C., Nijman H. W., Wilson G., Brooks S., Carinelli S., Provencher D., Hanzen C., Lutgens L. C. H. W., Smit V. T. H. B. M., Singh N., Do V., D'Amico R., Nout R. A., Feeney A., Verhoeven-Adema K. W., Putter H., Creutzberg C. L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P. J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Kruitwagen R. F. P. M., Hollema H., Pras E., Snyers A., Stalpers L., Jobsen J. J., Slot A., Mens J. -W. M., Stam T. C., Van Triest B., Van der Steen - Banasik E. M., De Winter K. A. J., Quinn M. A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Gribaudo S., Lissoni A. A., Ferrero A., Artioli G., Davidson C., McLachlin C. M., Ghatage P., Rittenberg P. V. C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., Tubiana-Mathieu N.

Background: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c059f44413e24aad8161bbc27656bb61
https://hdl.handle.net/2318/1904372

EP-1502 Endometrial cancer. Relapse free survival rates in our medium/large hospital in the UK

Autor: Price, L., Allerton, R.

Publikováno v: In Radiotherapy and Oncology April 2019 133 Supplement 1:S813-S813

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Help for infrastructure renewal : national technical guide sought

Autor: Allerton, R.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1674::1b75bb14b30ee58da360f94563c609a0
https://nrc-publications.canada.ca/eng/view/object/?id=997aceb5-6ae2-48ea-807b-5d94dc101d18